Processing your payment...
Please do not close your browser.

The Global Branded Generics Market Size Will Reach US$ 270.6 Billion By 2027, From US$ 535.8 Billion In 2022

Published on: May 2022

Let’s understand the market of Branded Generics

Patented medications are referred to as branded drugs. When a pharmaceutical company develops a novel medicine, it submits a patent application. Branded generics are generic versions of items supplied by either the original producer of the patented drug or generic manufacturers who have built up brand image for their generic versions of the treatment, which they present shortly after the original product's patent expires. Because a substantial number of healthcare products will become off-patent during the forecast period, the worldwide branded generics industry is expected to increase rapidly. Simple marketing authorisation procedures, new player entry, changing medication practices, and higher profit margins are all expected to boost the worldwide branded generics industry. Huge competition from branded pharmaceuticals and commodity generic products, on the other hand, are some of the restraints.

The market projection of Branded Generics

Ranked generics, also known as "value-added generics," can be an unique type of medication of an original patented drug or a similar drug with a specific trade name. Branded generics are distinct from 'commodity generics,' which are pharmaceutical drugs that are typically used as a replacement for innovator products once their patents expire. The international branded generics market is expected to increase slowly throughout the projection period of 2014 to 2025, since a substantial number of pharmaceutical items will become off-patent. Product type, distribution channel type, application, and geography all contribute to the worldwide branded generics market size. The global market size is divided into two types of products: Value-Added Branded Generics and Trade (Brand) Named Generics. Value-added branded generics are typically manufactured employing cutting-edge pharmaceutical technologies, enabling the achievement of the goal of making medications that are more patient-friendly. It must meet all bioequivalence requirements and be of comparable quality, effectiveness, and safety to the original medicine.

Different types of Branded Generics in the market

Commerce (Brand) Generics with one or more brand names are known as named generics. The same generic medicine may be manufactured by several businesses, each with their own brand name. The global market size for Cardiovascular Drugs, Anti-Cancer Drugs, CNS Drugs, Anti-Infective Drugs, and Others is divided by application. Cardiovascular medications are the fastest-growing segment of the branded generic drug industry. The expiration of patents for most CVS medications has made a significant contribution in this direction. The CNS Drugs market is predicted to rise from 2014 to 2025, owing to the rapid growth of several major antipsychotics and antidepressants, as well as the patent expiration of several key antipsychotics and antidepressants.

The global market size is divided into four types of distribution channels:

Hospital pharmacies, clinics, pharmacies, and drug stores. North America (US, Canada), Latin America (Mexico, Brazil), Western Europe (Germany, Italy, England, Spain, France, Rest of Western Europe), Eastern Europe (Russia), Asia Pacific (China, India, ASEAN, Australia & New Zealand, Japan), Middle East and Africa (GCC, South Africa, North Africa).

Regional Analysis of the Branded Generics Market

In 2014, North America had the largest market for branded generics, and it is expected to continue to lead the industry over the forecast period. This is owing to the rising demand for low-cost medications. For the past ten years, there has been fierce competition in Canada for the supply of generic pharmaceuticals. Europe is the second-largest market for branded generics, with major generic players focusing on the European market, where people cannot pay for expensive branded drugs. During the projection period, Asia Pacific is likely to develop slowly and account for the greatest market size globally. This is attributable to increased government financing and healthcare infrastructure.

Key players in the global market are as follows:

  • Teva Pharmaceutical Industries Ltd
  • Mylan N.V.
  • Hospira Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Apotex Inc.
  • GlaxoSmithKline Pharmaceuticals Limited
  • Valeant
  • ZydusCadila
  • Sandoz
  • Lupin Pharmaceuticals Inc.
  • Par Pharmaceutical Companies
  •  Sanofi
  •  AstraZeneca

The branded generics market is endless in its abilities and usage. To know more about this market in-depth, click on this <hyperlink> to get the expert report from Industry Data Analytics.

Explore more market insights in our expert corner! contact@industrydataanalytics.com